Like_老虎社区_美港股上老虎

Skylar217
2021-07-20

BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum

BioNTech SE is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc'

BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":171126168,"tweetId":"171126168","gmtCreate":1626719258754,"gmtModify":1631884943530,"author":{"id":3550145701881142,"idStr":"3550145701881142","authorId":3550145701881142,"authorIdStr":"3550145701881142","name":"Skylar217","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/171126168","repostId":1160801924,"repostType":4,"repost":{"id":"1160801924","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1626709874,"share":"https://www.laohu8.com/m/news/1160801924?lang=&edition=full","pubTime":"2021-07-19 23:51","market":"us","language":"en","title":"BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum","url":"https://stock-news.laohu8.com/highlight/detail?id=1160801924","media":"Benzinga","summary":"BioNTech SE is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc'","content":"<p><b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b>&nbsp;is&nbsp;buying a cell therapy R&amp;D platform plus a manufacturing site&nbsp;from&nbsp;<b>Gilead Science Inc's</b>GILD 0.91%Kite subsidiary.</p>\n<p>The deal gives BioNTech Kite's R&amp;D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.</p>\n<p>This program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).</p>\n<p>The acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.</p>\n<p>Financial terms were not disclosed.</p>\n<p>Kite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.</p>\n<p><b>Price Action:</b>&nbsp;BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-19 23:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b><a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a></b>&nbsp;is&nbsp;buying a cell therapy R&amp;D platform plus a manufacturing site&nbsp;from&nbsp;<b>Gilead Science Inc's</b>GILD 0.91%Kite subsidiary.</p>\n<p>The deal gives BioNTech Kite's R&amp;D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.</p>\n<p>This program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).</p>\n<p>The acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.</p>\n<p>Financial terms were not disclosed.</p>\n<p>Kite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.</p>\n<p><b>Price Action:</b>&nbsp;BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160801924","content_text":"BioNTech SE is buying a cell therapy R&D platform plus a manufacturing site from Gilead Science Inc'sGILD 0.91%Kite subsidiary.\nThe deal gives BioNTech Kite's R&D IP for its personalized solid tumor neoantigen T cell receptor (TCR) work and the manufacturing center in Gaithersburg, MD, which supplies the clinical trial product.\nThis program builds and further extends BioNTech's leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).\nThe acquired Gaithersburg facility will provide production capacity to support clinical trials in the U.S. and complement BioNTech's existing cell therapy manufacturing facility in Germany.\nFinancial terms were not disclosed.\nKite's new manufacturing facility in Frederick, MD, for commercial production of CAR T-cell therapy is not part of the purchase agreement.\nPrice Action: BNTX shares are up 0.86% at $233.46 during the market session on the last check Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":194,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

BioNTech Snaps Up Solid Tumor TCR Platform, Manufacturing Site From Gilead For Undisclosed Sum

评论（3）

热议股票